Video

Dr. Dorff on state of second-line treatment for metastatic urothelial cancer

Author(s):

Urology Times staff

Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.

Related Videos
Neeraja Tillu, MD, answers a question during a Zoom video interview
2 experts in this video
2 experts in this video
Related Content
Nadofaragene firadenovec maintains safety, efficacy in real-world population
March 20th 2025

Nadofaragene firadenovec maintains safety, efficacy in real-world population

Mark D. Tyson, MD, MPH Jacob A. Moyer, BS Hannah Clarke
"The implication for real-world decision-making is that this drug appears to hold up to what was seen in the trial," says Mark D. Tyson II, MD, MPH.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
March 14th 2025

What determines the optimal urinary diversion?

Anne K. Schuckman, MD
"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC
February 24th 2025

Neoadjuvant APL-1202 plus tislelizumab is safe in patients with MIBC

Hannah Clarke
The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.
FDA approves expanded access program to provide alternative source of BCG
February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke
According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.
© 2025 MJH Life Sciences

All rights reserved.